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The chemokine receptors are seven trans-
membrane, G-protein-coupled surface 
receptors that play key roles in the migra-
tion and localization of leuko cytes to the 
skin during physiologic and inflammato-
ry states. Their ligands, chemokines, are 
small (8–11 kDa) secreted proteins that 
are predominantly involved in regulat-
ing leukocyte chemoattraction (Lonsdorf 
et al., 2009). Within this chemokine net-
work, there is considerable redundancy; 
multiple chemokines may bind a single 
receptor and vice versa. Functionally, 
chemokine receptors facilitate direc-
tional migration toward an increasing 
gradient of specific ligand(s). Moreover, 
chemokines activate leukocyte surface 
integrins, facilitating firm adhesion of 
white blood cells to vascular endotheli-
um through immunoglobulin superfam-
ily members at sites of inflammation and 
initiating a crucial step in the multistep 
paradigm of leukocyte recruitment. The 
release of specific chemokines at inflam-
matory sites in a time-dependent manner 
determines the order in which leukocyte 
(or T-cell) subsets enter inflamed sites 
such as skin. Recent data indicate that 
known subsets of Th cells express signa-
ture chemokine receptors (e.g., CXCR3, 
CCR3/4, and CCR6) that help to define 
individual subsets such as Th1, Th2, and 
Th17 cells, respectively, although there 
is some degree of overlap among these 
T-cell subsets. Thus, chemokine receptor 
repertoires define T-cell subsets pheno-
typically and functionally, determining 
their tissue tropism. This concept has 
importance physiologically and patho-
logically, given that distinct effector T-cell 
subsets are preferentially recruited in dif-
ferent inflammatory skin diseases.
Skin-homing T cells express 
glycosylated antigenic epitopes known 
as “cutaneous lymphocyte-associated 
antigens” (CLAs), enabling their spe-
cific binding to E-selectin, an adhesion 
molecule highly expressed on inflamed 
endothelium in skin. Binding to E-selectin 
initiates T-cell rolling interactions on 
vascular endothelium, the first step in 
the multistep recruitment paradigm 
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(Fuhlbrigge et al., 1997). A large major-
ity of peripheral blood CLA+ lympho-
cytes co-express CCR4 (Campbell et al., 
1999), with approximately 40% showing 
additional expression of CCR10 (Hudak 
et al., 2002). The ligands for CCR4 are 
CCL17 and CCL22. Multiple skin-derived 
cell types have been shown to synthe-
size CCL17, including keratinocytes, 
activated macrophages, dendritic cells 
(DCs), and endothelial cells. The signifi-
cant role of this molecule in skin homing 
is supported by immuno histochemical 
evidence showing constitutive and 
inducible expression of CCL17 by cuta-
neous venules as well as by keratinocytes 
in the epidermis. Additionally, integrin-
dependent arrest of CLA+ T cells on cuta-
neous venules is triggered by CCR4 and 
its ligands (Campbell et al., 1999).
It should be noted that CCL17 is only 
one of many chemokines expressed in 
skin (Lonsdorf et al., 2009). CCL27, for 
example, is also expressed in the basal 
layer of the epidermis, and its receptor, 
CCR10, is produced by a subset of CLA+ 
T cells. Homey et al. (2002) have shown 
that targeting CCL27 can ameliorate 
allergen-induced inflammation. Some 
investigators have proposed that CCR4 
function in cutaneous recruitment may 
overlap with CCR10 because inhibition 
of both CCR4 and CCR10 function was 
required to block contact dermatitis fully 
in mice (Reiss et al., 2001). Recent data 
indicate that under some conditions, 
however, CCR4 appears to have unique 
functions in the recruitment of skin-
homing T cells that are not shared with 
CCR10 (Campbell et al., 2007). Based 
on these models, CCR4 exhibits vary-
ing degrees of contribution to skin traf-
ficking, depending on the inflammatory 
model used.
Until recently, CCR4 was thought to 
be expressed preferentially by Th2 cells 
(Sallusto et al., 1998), but it appears that 
many T-cell subsets can express CCR4 to 
varying degrees. In some inflammatory 
models, CCR4+ T cells express cytokine 
profiles consistent with Th1 and Th17 
cells (Campbell et al., 2007). CCR4 has 
also been found on Foxp3+ regulatory T 
cells (Tregs) and is critical for skin local-
ization and suppression of cutaneous 
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inflammatory responses (Sather et al., 
2007). More recently, Duhen et al. (2009) 
have defined the Th22 subset, character-
ized by expression of CCR10, CCR4, 
CCR6, and CLA as well as by the produc-
tion of IL-22, but not IL-17 or IFN-γ.
In this issue, Lehtimäki et al. describe 
their use of an oxazolone-induced con-
tact hypersensitivity (CHS) model to 
show that T cells (as well as neutrophils 
and eosinophils) from CCR4–/− mice 
accumulate just as (if not more) effi-
ciently in inflamed skin compared with 
the same population of leukocytes from 
wild-type (WT) mice. Furthermore, CHS 
in CCR4–/− mice (as measured by ear 
swelling response) was increased moder-
ately compared with CHS in WT mice. 
These findings are similar to those pub-
lished by Reiss et al. (2001), who dem-
onstrated that CCR4-deficient mice had 
equivalent lymphocyte accumulation 
in ear skin and a modest increase in 
ear swelling compared with WT mice 
following sensitized challenge to the 
allergen DNFB. Surprisingly, in both of 
these models, similar modest increases 
in ear swelling and T-cell infiltration were 
found in the CCR4-deficient group rela-
tive to WT controls. Therefore, it appears 
that, under the conditions defined in 
these two models, loss of CCR4 may 
actually promote inflammation and T-cell 
accumulation within the skin. Reiss and 
colleagues (2001) have further shown 
that CCR4−/− mice treated with anti-
CCL27-neutralizing antibodies (CCR10 
ligand) have dramatically reduced cuta-
neous lymphocyte localization and ear 
swelling compared with CCR4 deficien-
cy alone. Interestingly, the anti-CCL27 
antibodies alone had a negligible impact 
on CHS by each of the quant ifiable 
criteria used. Taken together, the results 
from these two publications suggest 
that CCR4 and CCR10 pathways may 
serve redundant functions; either alone 
is sufficient for skin homing and effec-
tor function in these CHS models. These 
results make sense in that CCR10 and 
CCR4 are (to varying degrees) expressed 
in the CLA+ population of skin-homing 
T cells. Intriguingly, these results suggest 
that the isolated loss of CCR4 promotes, 
rather than prevents, the development of 
skin inflammation and T-cell homing.
In other models, CCR4 may have 
an obligatory role in T-cell recruit-
ment to skin. Specifically, Campbell 
et al. (2007) developed an ovalbumin 
peptide–specific TCR skin inflammation 
model that demonstrated that CCR4 is 
critical for T-cell homing to the skin and 
subsequent inflammation. Unfortunately, 
this model cannot be readily com-
pared with the current study or other 
oxazolone/DNFB-induced CHS models.
Reconciling the role of CCR4 in skin 
physiology and pathology is not easy. 
The expression of CCR4 by Tregs could 
potentially help explain the surprising 
results yielded by Lehtimäki et al. (2010) 
and Reiss et al. (2001). Sather et al. 
(2007) showed that CCR4-deficient Tregs 
have impaired skin homing, leading to 
severe, tissue-selective inflammation and 
effector T-cell infiltration of the skin and 
lung. Lehtimäki et al. (2010), however, 
reported that, within the oxazolone CHS 
model, the number of Tregs was found to 
be significantly elevated within the skin 
of CCR4–/− mice relative to WT mice (i.e., 
Foxp3 mRNA was increased dramatically 
in inflamed skin, whereas CD4+Foxp3+ 
cells were approximately doubled in skin 
samples by immunohisto chemistry and 
moderately increased as demonstrated 
by flow cytometry). It appears that in 
the oxazolone model, skin trafficking of 
Tregs is not dependent on CCR4; howev-
er, redundant function of CCR10 in skin 
homing cannot be excluded because the 
authors report that 10% of Treg cells iso-
lated from the lymph nodes of oxazolone-
treated mice expressed CCR10. It has 
not been ruled out, however, that the 
increase in Tregs seen in CCR4–/− mice 
might simply reflect an enhanced recruit-
ment of Tregs to skin through CCR10 (or 
other chemokine receptors) because of a 
secondary phenomenon in response to 
the vigorous skin inflammation present in 
CCR4-deficient mice.
Interestingly, the Treg effector cyto-
kines, IL-10 and TGF-β, were elevated 
only minimally relative to the dramatic 
increase noted for Foxp3 mRNA in 
CCR4–/− mice, suggesting that, despite 
the increased numbers of Foxp3+ cells, 
regulatory function might be defective in 
the absence of CCR4. Rightly, the authors 
note that these cytokines are not restrict-
ed to Tregs and, therefore, Treg effector 
Figure 1. Possible mechanisms by which ccr4 might regulate skin inflammation. (1) CCR4 and/or 
CCR10 may directly influence migrations of effector (Teff) or regulatory T (Treg) cells into skin through 
dermal blood vessels. In some model systems, CCR10 and CCR4 are redundant in terms of driving 
inflammation. (2) Attraction of relatively undifferentiated T cells with skin dendritic cells (DCs) may 
drive T cells toward suppressive or effector phenotypes. (3) Localization of T cells in epidermis may 
be influenced by CCL17 expressed in the epidermis. CCR10 may also have a role because its ligand, 
CCL27, is produced in basal keratinocytes.
|Chemokine receptors are both positive and negative mediators of 
skin inflammation.
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function cannot be fully evaluated. 
Because Treg homing remains intact, we 
propose that a defect in Treg function (but 
not necessarily homing) might account 
for the results observed with the CCR4–/− 
mice. To test this hypothesis, in vitro T-cell 
suppressor assays may be performed 
using Tregs isolated from oxazolone-
treated skin of WT and CCR4–/− mice.
Additional hypotheses may explain 
the unexpected results presented by 
Lehtimäki et al. (2010). As discussed 
previously, multiple cell types, including 
endothelial cells, DCs, and keratino-
cytes, produce CCL17. CCR4 may be 
dispensable with respect to recruitment 
of T cells into the skin (section 1 in Figure 
1), with CCR10 playing a compensatory 
role in the absence of CCR4, but events 
downstream of initial recruitment may be 
important. Secretion of CCL17 by DCs 
is believed to mediate DC–T-cell inter-
actions. Upon maturation, DCs have 
been shown to produce CCL17, which 
mediates attraction and adhesion of these 
DCs to antigen-primed T cells (Wu et al., 
2001). In particular, these interactions 
may be important for the in situ develop-
ment of effector and regulatory T-cell acti-
vation (section 2 in Figure 1). The lack of 
interaction between DCs and Tregs due 
to lack of CCR4 on Tregs is another possi-
ble explanation for the enhanced inflam-
mation seen in CCR4–/− mice. Finally, 
keratinocytes also synthesize CCL17, 
which may be important for epidermo-
tropism of both memory effector T cells 
and Tregs (section 3 in Figure 1). Correct 
localization of T-cell populations within 
the epidermis might alter inflammatory 
responses. For these reasons, future stud-
ies should address events downstream of 
tissue homing: specifically Treg/DC and 
T-cell/keratinocyte interactions.
It is becoming clearer that chemokine 
receptors are not always positive media-
tors of skin inflammation, but that they 
can be critical for suppression of inflam-
mation as well. What complicates the 
picture is that some receptors, as exem-
plified by CCR4, may act in both ways. 
Depending on the model of inflamma-
tion used, CCR4’s effects can influence 
inflammation in different, almost con-
tradictory, ways. Indeed, the nuances 
and complexities of chemokine receptor 
function in the skin are just beginning to 
be discerned at a fine level.
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Paying “Particle” Attention to novel 
Melanoma Treatment Strategies
Michele B. Weiss1 and Andrew E. Aplin1
Malignant melanoma remains the deadliest form of skin cancer because of its high-
ly aggressive nature and the lack of effective treatments. Recent invest igations into 
alternative treatment strategies have highlighted the exciting potential of nanopar-
ticles to increase melanoma cell delivery and the efficacy of small inter fering RnAs 
(siRnAs) and pharmacological inhibitors. In this issue, Chen et al. report a new 
liposomal nanoparticle for c-Myc siRnA delivery, noting it to be highly effective 
in reducing c-Myc expression and inhibiting melanoma tumor growth in mouse 
models. This preclinical study underscores the importance of investigating nano-
particle treatment options for chemoresistant melanomas.
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Introduction
The field of targeted therapeutic strat egies 
for melanoma is entering exciting times. 
Malignant melanoma is the deadliest form 
of skin cancer and has for decades repre-
sented a paradigm for chemoresistance. 
Current therapeutic options are poor and 
no new US Food and Drug Administration 
(FDA)-approved drugs have emerged in 
recent years. Current melanoma treatment 
mainstays, such as the alkylating agent 
dacarbazine and the immune-stimulating 
agent IL-2, are plagued by a lack of clini-
cal benefit in the majority of patients and 
numerous side effects. However, highly 
